AFM
PTHS

Anson Funds Management’s Pelthos Therapeutics PTHS Stock Holding History

Anson Funds Management’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,103
Closed -$265K – 209
2024
Q2 		$265K Sell
20,103
-5,086
-20% -$85.6K 0.03% 137
2024
Q1 		$660K Buy
+25,189
New +$882K 0.04% 113

Other funds holding PTHS

APP
Avantax Planning Partners Dubuque, Iowa $3.64B AUM 14.73% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Anson Funds Management's PTHS Position: Q3 2024 in Review

Anson Funds Management sold out of Pelthos Therapeutics (PTHS) in Q3 2024, closing a stake of 20,103 shares — an estimated $265K sold.

Anson Funds Management first reported a position in PTHS in Q1 2024 and held it in 2 quarters. The position peaked at $660K in Q1 2024. 5 funds tracked by Wall St. Rank hold PTHS as of Q3 2024.

  • Anson Funds Management reported no remaining Pelthos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Anson Funds Management sold 20,103 Pelthos Therapeutics shares in Q3 2024, an estimated $265K.
  • Anson Funds Management first reported a position in Pelthos Therapeutics in Q1 2024 and held it in 2 quarters.
  • Anson Funds Management's Pelthos Therapeutics position peaked at $660K in Q1 2024.
  • 5 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q3 2024.

Based on Anson Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.